Level Bio Balance Sheet Health
Financial Health criteria checks 4/6
Level Bio has a total shareholder equity of SEK5.5M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK15.1M and SEK9.6M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 1.34m |
| Equity | SEK 5.54m |
| Total liabilities | SEK 9.57m |
| Total assets | SEK 15.11m |
Recent financial health updates
No updates
Recent updates
Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?
Jun 02
Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?
Feb 10I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease
Nov 03AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected
Aug 18Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?
Mar 07Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?
Nov 22Financial Position Analysis
Short Term Liabilities: LEVBIO's short term assets (SEK11.0M) exceed its short term liabilities (SEK9.1M).
Long Term Liabilities: LEVBIO's short term assets (SEK11.0M) exceed its long term liabilities (SEK450.0K).
Debt to Equity History and Analysis
Debt Level: LEVBIO is debt free.
Reducing Debt: LEVBIO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LEVBIO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LEVBIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.9% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 08:05 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Level Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|